Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't want

May 5, 2026 09:25 AM EDTUpdated 01:08 PM DealsPharma Up­dat­ed: Madri­gal ex­tends MASH deal streak with Ar­row­head drug that J&J did­n't want Kyle LaHucik Biotech Correspondent Madri­gal Phar­ma­ceu­ti­cals has made its fourth MASH deal in 10 months, fur­ther sig­nal­ing its am­bi­tions to be not just the first drug­mak­er for the fat­ty … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER